Epitopia ApS
CVRCVR number42134015Opløst
Company financials
Key figures
Updated 30 Jun 2025
- Return on assets
- -11.4%
- Return on equity
- -25.4%
- Current ratio
- 135.6%
- Equity ratio
- 26.3%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -18,888 |
Operating profit | -18,888 |
Finance income | 4,739 |
Finance expenses | 0 |
Tax expense | -3,113 |
Profit/loss for the year | -11,036 |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 154,315 |
Current assets | 165,609 |
Total assets | 165,609 |
Equity | 43,522 |
Liabilities | 122,087 |
Current liabilities | 122,087 |
Working capital
| Reporting period | |
|---|---|
Other current receivables | 5,381 |
Trade payables | 15,000 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 40,404 |
Retained earnings | 3,118 |
Annual report highlights
Official annual report · 2024Open official report
Business and development
Primary activities
Description of key activities of the company
The company's purpose is to own capital shares in other companies and make investments and related activities at the board's discretion, as well as to conduct research and development activities within biotechnology with regards to the development of drugs for cancer and autoimmune diseases and vaccine development as well as other related activities.
Development in activities and financial affairs
Significant changes in the company's activities and financial matters
There have been no significant changes in activities and financial matters.…
Commitments and security
Contingent liabilities
1. Contingencies
Joint taxation…
Mortgages and collateral
2. Charges and security
The company have no charges or security
Create a free account to see up to 9 years of financial history
Create free account